The Claim

In Pkd1RC/RC mice, fenofibrate treatment is associated with reduced kidney cyst cell proliferation and decreased infiltration of inflammatory cells, including M2-like macrophages, indicating potential anti-proliferative and anti-inflammatory effects in the context of polycystic kidney disease.

Source: PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
12score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In mice with a genetic form of kidney disease, taking a drug called fenofibrate seems to slow down the growth of kidney cysts and reduce harmful inflammation in the kidneys.

See the scientific wording

In Pkd1RC/RC mice, fenofibrate treatment is associated with reduced kidney cyst cell proliferation and decreased infiltration of inflammatory cells, including M2-like macrophages, suggesting anti-proliferative and anti-inflammatory effects in the context of polycystic kidney disease.

What the research says

1 study

  1. Study: PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

    The study gave fenofibrate to mice with a disease like polycystic kidney disease and found it reduced kidney cyst growth and inflammation, just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.